The Methodist Hospital Research Institute
Patrick McCulloch,MD
This study is designed as a prospective, open label, single arm pilot clinical study that will establish the safety and efficacy of a single injection of mesenchymal stromal cells in patients. Each subject will receive one intra-articular injection of autologous mesenchymal stromal cells derived from infrapatellar fat pad (FP-MSC) tissue samples collected from the subject during anterior cruciate ligament (ACL) reconstruction surgery.
Anterior Cruciate Ligament Reconstruction
Autologous Mesenchymal Stromal Cells
PHASE1
Study Type : | INTERVENTIONAL |
Estimated Enrollment : | 15 participants |
Masking : | NONE |
Primary Purpose : | TREATMENT |
Official Title : | Anterior Cruciate Ligament (ACL) Reconstruction With Autologous Fat Pad Derived Mesenchymal Stem Cells |
Actual Study Start Date : | 2025-08 |
Estimated Primary Completion Date : | 2028-03 |
Estimated Study Completion Date : | 2030-03 |
Information not available for Arms and Intervention/treatment
Ages Eligible for Study: | 18 Years |
Sexes Eligible for Study: | ALL |
Accepts Healthy Volunteers: |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
RECRUITING
Houston Methodist Hospital
Houston, Texas, United States, 77030